001482813 000__ 06800cam\\22005777a\4500
001482813 001__ 1482813
001482813 003__ OCoLC
001482813 005__ 20231128003352.0
001482813 006__ m\\\\\o\\d\\\\\\\\
001482813 007__ cr\un\nnnunnun
001482813 008__ 231105s2023\\\\si\\\\\\o\\\\\100\0\eng\d
001482813 019__ $$a1407314803$$a1409394117
001482813 020__ $$a9789819952311$$q(electronic bk.)
001482813 020__ $$a981995231X$$q(electronic bk.)
001482813 020__ $$z9819952301
001482813 020__ $$z9789819952304
001482813 0247_ $$a10.1007/978-981-99-5231-1$$2doi
001482813 035__ $$aSP(OCoLC)1407278478
001482813 040__ $$aYDX$$beng$$cYDX$$dGW5XE$$dEBLCP$$dAU@$$dSFB
001482813 049__ $$aISEA
001482813 050_4 $$aRC280.B8
001482813 08204 $$a616.99/449$$223/eng/20231116
001482813 1102_ $$aJapanese Organization of Hereditary Breast and Ovarian Cancer.$$bAnnual Meeting$$d(2021)
001482813 24510 $$aPractical guide to hereditary breast and ovarian cancer :$$bannual meeting of the Japanese Organization of Hereditary Breast and Ovarian Cancer 2021 /$$cDaisuke Aoki, Seigo Nakamura, Yoshio Miki, editors.
001482813 260__ $$aSingapore :$$bSpringer,$$c2023.
001482813 300__ $$a1 online resource
001482813 336__ $$atext$$btxt$$2rdacontent
001482813 337__ $$acomputer$$bc$$2rdamedia
001482813 338__ $$aonline resource$$bcr$$2rdacarrier
001482813 504__ $$aReferences -- Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine -- 1 Introduction -- 2 Characteristics of HBOC Ovarian Cancer -- 3 PARP Inhibitor -- 4 Biomarkers of PARP Inhibitors -- 4.1 Platinum-Sensitivity Status -- 4.2 BRCA1/2 Testing -- 4.3 SNP-Based Genomic Scar Assays -- 5 New Candidates for Evaluating HRD Status -- 5.1 Homologous Recombination Repair (HRR)-Related Gene Mutations -- 5.2 Mutation Signatures -- 6 Clinical Use of PARP Inhibitors for Ovarian Cancer in Japan -- 7 Conclusion -- References -- Part III: Basic Science
001482813 5050_ $$aIntro -- Contents -- Part I: Breast -- Establishment of a Medical System with HBOC in Mind -- 1 Introduction -- 1.1 History of BRCA1/2 Clinical Practice in Japan -- 1.2 BRCA1/2 Genetic Test -- 1.3 Risk Reduction Surgery -- 1.4 Surveillance -- 1.5 PARP Inhibitor -- 1.6 Chemoprevention -- 1.7 Beyond HBOC -- 1.8 Genetic Test for Family -- 2 Conclusion -- References -- Guidelines for Diagnosis and Treatment of HBOC: Methods and Products -- 1 Purpose of the Guidelines -- 2 Significance of Guideline Creation -- 3 Method of Preparation of These Guidelines -- 3.1 Preparation Members
001482813 5058_ $$a3.2 Establishment of Clinical Queries -- 3.3 Systematic Review and Evidence Synthesis -- 3.4 Recommendation-Making -- 4 Type of Recommendation -- 5 External Evaluation -- 6 Summary -- HBOC from a Plastic Surgeon's Perspective -- 1 Breast Reconstruction in Japan -- 2 RRM and Breast Reconstruction for HBOC in the Era of Self-Funded Treatment -- 3 BIA-ALCL and the "Allergan Crisis" in Japan -- 4 Properly Fearing BIA-ALCL -- 5 Breast Reconstruction After RRM After Insurance Coverage of RRM -- 6 Fat Grafting -- 7 Lifestyle and Life Stage -- References -- Part II: Gynecology
001482813 5058_ $$aSerous Tubal Intraepithelial Carcinoma (STIC) and Precancerous Lesions in Risk-Reducing Salpingo-oophorectomy (RRSO) Specimens -- 1 Introduction -- 2 HBOC and Ovarian Cancer -- 3 Significance of RRSO and Pathological Examination -- 4 Occult Cancer in RRSO Specimens -- 5 Precancerous Lesions in RRSO Specimens -- 5.1 STIC -- 5.1.1 STIC in RRSO Specimens -- 5.1.2 STIC Coexisting with HGSC -- 5.1.3 STIC in Benign Gynecological Specimens -- 5.2 STIL, p53 Signature -- 5.2.1 Frequencies of STIL and p53 Signature (Table 1) -- 5.2.2 Significance of p53 Signature and STIL -- 6 Future Prospective
001482813 5058_ $$aHeterogeneities in Hereditary Cancer Genes as Revealed by a Large-Scale Genome Analysis -- 1 Background -- 1.1 Limited Information on Personalized Medicine for BRCA1 and BRCA2 -- 1.2 Importance of Large-Scale Data -- 2 Risk and Frequency of Pathogenic Variants in 27 Hereditary Cancer Genes -- 2.1 BioBank Japan -- 2.2 Sequencing -- 2.3 Clinical Interpretation of Genetic Variants -- 2.4 Unified Analysis of >66,000 Individuals with Five Cancer Types -- 2.5 Risk and Frequency of Pathogenic Variants -- 2.6 Variants of Uncertain Significance -- 3 Heterogeneity -- 3.1 Between Genes
001482813 506__ $$aAccess limited to authorized users.
001482813 520__ $$aThis book shares cutting-edge evidence on Hereditary Breast and Ovarian Cancer (HBOC) treatment, delivering facts on breast cancer, gynecologic oncology, and basic research to contribute to clinicians' practices. Each chapter presents the latest clinical techniques, basic experimental results, and the best-chosen research findings. The book is based on the works presented at the Japanese Organization of Hereditary Brest and Ovarian Cancer (JOHBOC) and a special chapter delivers a study based on the extensive data from the Japanese HBOC patients registered in the society's database, presenting novel evidence for further advancement in the field. The practice for HBOC has been rapidly increasing due to the clinical development of poly(ADP-ribose) polymerase inhibitors and the spread of companion diagnostics. In addition, the insurance coverage of a part of HBOC treatment raised social awareness in Japan, and the book illustrates not only clinical efforts but also issues related to the social system and the efforts of the association of related organizations. Hereditary Breast and Ovarian Cancer Annual meeting of JOHBOC will be of interest to breast surgeons, obstetricians and gynecologists, pancreatic cancer surgeons, and urologists engaged in HBOC treatment through the implementation of companion diagnostics for PARP inhibitors administration. Also, physicians occupied in genetic medicine who perform genetic testing and medical staff practicing HBOC will find this book insightful. It is also for HBOC patients and their families, medical administrators in the social system of HBOC practice. Editors and authors hope to contribute to the equalization and widespread of HBOC practice and serve as a foundation for future advances in the disease's treatment and medical practice.
001482813 650_0 $$aBreast$$xCancer$$xGenetic aspects$$vCongresses.$$0(DLC)sh2006006447
001482813 650_0 $$aOvaries$$xCancer$$xGenetic aspects$$vCongresses.$$xCancer$$xPatients$$zUnited States$$vBiography$$0(DLC)sh2010009909
001482813 655_0 $$aElectronic books.
001482813 7001_ $$aAoki, Daisuke.
001482813 7001_ $$aNakamura, Seigo.
001482813 7001_ $$aMiki, Yoshio$$c(Of Tōkyō Ika Shika Daigaku)
001482813 77608 $$iPrint version: $$z9819952301$$z9789819952304$$w(OCoLC)1389339426
001482813 852__ $$bebk
001482813 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-99-5231-1$$zOnline Access$$91397441.1
001482813 909CO $$ooai:library.usi.edu:1482813$$pGLOBAL_SET
001482813 980__ $$aBIB
001482813 980__ $$aEBOOK
001482813 982__ $$aEbook
001482813 983__ $$aOnline
001482813 994__ $$a92$$bISE